The investment is intended to support the company’s global growth, including strategic scaling in China, key Asia Pacific markets and Travel Retail.
Augustinus Bader was launched in 2018 by Professor Augustinus Bader, a biomedical scientist and expert in regenerative medicine, and financier Charles Rosier, co-founder and CEO. The company’s products are formulated with TFC8 technology and backed by three decades of research in skin healing and tissue repair.
Having achieved “unicorn” status four years after launch, Augustinus Bader has earned cult positioning in the beauty industry with its science-backed technology. The company’s research-led approach and commitment to skin and hair health has delivered disruptive products – including its hero products The Rich Cream and The Cream – amassing more than 100 global awards in just four years.
The investment is intended to support the company’s global growth, including strategic scaling in China, key Asia Pacific markets and Travel Retail. In addition, Augustinus Bader plans to drive increased brand awareness and marketing initiatives to maximize continued expansion in the U.S. market.
Charles Rosier commented, “Reaching unicorn status is a very proud moment for the Augustinus Bader brand. We welcome an investor group of this caliber to our shareholder base as we focus on the strategic expansion of our business. We believe there is a significant opportunity to reach more customers globally and look forward to Augustinus Bader’s next phase of growth as we aim to redefine luxury skin and hair care.”